This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.
Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers
by Swarup Gupta
The index made strong gains this week as investors shrugged off trade tensions.
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
by Zacks Equity Research
Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
by Zacks Equity Research
In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
by Zacks Equity Research
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
by Zacks Equity Research
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
by Zacks Equity Research
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.
Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
by Swarup Gupta
The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.
3 Small Biotech Stocks That Almost Doubled in Past Month
by Zacks Equity Research
We take a look at three biotech stocks, prices of which have almost doubled in the past month.
Exelixis' Cabometyx Recommended by NCCN for All Types of RCC
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx gets updated recommendations from the NCCN.
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.
Dow 30 Stock Roundup: Coca-Cola Buys Costa, DowDuPont Earnings Impress
by Swarup Gupta
The index remained weighed down by trade tensions during a holiday-shortened week.
Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.
Large Cap Pharma Stocks Staging a Comeback in Second Half
by Indrajit Bandyopadhyay
Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.
The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines
Top Analyst Reports for Pfizer, Salesforce & ADP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Salesforce (CRM) and ADP (ADP).